(1-aziridiny1)-1,4-benzoquinone | 4370-53-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1-aziridiny1)-1,4-benzoquinone
• 英文别名: 2-Aethylenimino-p-benzochinon；aziridinyl 1,4-benzoquinone；aziridinyl-benzoquinone；Aziridinylbenzoquinon；ethyleniminoquinone；aziridinyl quinone；ethyleniminquinone；2,5-Cyclohexadiene-1,4-dione, 2-(1-aziridinyl)-；2-(aziridin-1-yl)cyclohexa-2,5-diene-1,4-dione
• CAS: 4370-53-0
• 化学式: C₈H₇NO₂
• 分子量: 149.149
• InChiKey: HDHPYSLJOGMXSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  37.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  乙烯亚胺 、 对苯醌 在 potassium dihydrogenphosphate 作用下， 以 氯仿 、 水 为溶剂， 反应 4.0h， 以33.6%的产率得到(1-aziridiny1)-1,4-benzoquinone
  参考文献：
  名称：

  Untersuchungen �ber Chinone, 10. Mitt. Zur Reaktion vonp-Benzochinon mit sekund�ren aliphatischen Aminen

  摘要：

  p-Benzoquinone (1) reacts with dialkylamines 2a-d to 2-dialkylamino-p-benzoquinones 3, 2,5-bis-dialkylamino-p-benzoquinones 4, 2-dialkylamino-8-hydroxydibenzofuran-1,4-quinones 5, and in pyridine also to 2-dialkylamino-5-p-hydroxy-phenoxy-p-benzoquinones 6. A method affording almost exclusively 3 has been developed which is also applicable to compounds 2e-h.

  DOI：

  10.1007/bf00807099

文献信息

• ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20170355769A1

  公开（公告）日：2017-12-14

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  这项发明涉及B7同源物3蛋白（B7-H3）抗体和抗体药物结合物（ADCs），包括使用所述抗体和ADCs的组合物和方法。
• [EN] COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF<br/>[FR] COMPOSÉS COMPRENANT UN LIEUR CLIVABLE ET LEURS UTILISATIONS
  申请人：INTOCELL INC

  公开号：WO2019008441A1

  公开（公告）日：2019-01-10

  Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

  提供了一种包括可切割连接物的化合物，其用途，以及用于制备该化合物的中间体化合物，更具体地，本发明的包括可切割连接物的化合物可能包括具有特定功能或活性的活性剂（例如，药物，毒素，配体，用于检测的探针等），能够选择性释放活性剂的SO2官能团，以及通过外部刺激触发化学反应，物理化学反应和/或生物反应的官能团，并且还可以包括具有与所需靶受体结合特异性的配体（例如，寡肽，多肽，抗体等）。
• Cytotoxic N-unsubstituted indoles and cyclopent(b)indoles and method of making and using same
  申请人：——

  公开号：US20040006054A1

  公开（公告）日：2004-01-08

  The merits of N-unsubstituted indoles and cyclopent[b]indoles as DNA-directed reductive alkylating agents are described. These systems represent a significant departure from N-substituted and pyrrolo[1,2-a] fused systems such as the mitomycins and mitosenes. The cyclopent[b]indole—based aziridinylquinone, when bearing an acetate leaving group, was found to be cytotoxic and displayed significant in vivo activity against syngeneic tumor implants. This particular analogue was unexpectedly superior to the others studied, both in terms of high specificity for the activating enzyme DT-diaphorase and in high % DNA alkylation. Alkylation by a quinone methide intermediate as well as by the aziridinyl group were examined for crosslinking. The possible metabolites of the most active indole species were prepared and found to retain cytotoxicity, strongly suggesting that in vivo activity could also be sustained. The indole systems in the present invention display selectivity for melanoma and for non small cell lung, colon, renal, and prostate cancers when administered in an effective amount. The cancer specificity observed is believed to pertain to differential substrate specificity for DT-diaphorase.

  描述了N-未取代吲哚和环戊[b]吲哚作为DNA定向还原烷基化剂的优点。这些体系与N-取代和吡咯[1,2-a]融合体系（如丝菌素和丝菌烯）有显著不同。基于环戊[b]吲哚的氮杂环喹喙醌，当带有乙酸离去基团时，被发现具有细胞毒性，并对同基因肿瘤移植物显示出显著的体内活性。这种特定的类似物在高度特异性激活酶DT-二氧还酶和高DNA烷基化百分比方面意外地优于其他研究过的类似物。通过醌亚甲基中间体和环氧丙基基团进行了交联的烷基化研究。最活跃的吲哚物种的可能代谢产物已经制备并发现保留了细胞毒性，强烈暗示体内活性也可能持续存在。本发明中的吲哚体系在有效剂量下对黑色素瘤和非小细胞肺癌、结肠癌、肾癌和前列腺癌显示出选择性。观察到的癌症特异性被认为与DT-二氧还酶的不同底物特异性有关。
• [EN] ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT COMPRENANT DES ANTICORPS ANTI-B7-H3
  申请人：INTOCELL INC

  公开号：WO2021260438A1

  公开（公告）日：2021-12-30

  The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications

  本公开涉及抗体药物结合物（ADCs），其中一个或多个活性剂通过连接剂与抗B7-H3抗体结合。连接剂可能包括一个单位，将活性剂共价连接到抗体上。本公开进一步涉及特异性结合B7-H3的单克隆抗体和抗原结合片段、变体、多聚体版本或双特异性抗体，以及在各种治疗、诊断和预防适应症中制备和使用这些抗B7-H3抗体和抗原结合片段的方法。
• THREE-STEP PRETARGETING METHODS AND COMPOUNDS
  申请人：——

  公开号：US20020015705A1

  公开（公告）日：2002-02-07

  Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, three-step pretargeting methods are described.

  涉及预定位递送诊断和治疗药物的方法、化合物、组合物和试剂盒已被披露。具体而言，描述了三步预定位方法。